ReviewBMB reports2026
SLC39 and SLC30 zinc transporters: functions and potential mechanisms in cancer.
Review in BMB reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solute carrier (SLC) transporters are membrane proteins that facilitate the movement of various substrates, such as nutrients and organic or inorganic ions, across cellular membranes. Recent studies underscore the critical roles of SLC transporters in regulating cancer metabolism, immune evasion, and the tumor microenvironment. Increasing evidence suggests that the SLC39 and SLC30 families of zinc transporters, responsible for importing and exporting zinc into and out of the cytoplasm, respectively, modulate intracellular zinc distribution and signaling and may play a role in cancer initiation or progression. In this review, we discuss the functional roles of these zinc transporters in different cancer types and examine potential mechanisms linking zinc metabolism with oncogenic pathways that contribute to malignancy. [BMB Reports 2026; 59(5): 262-272].
Indexed as
Identifiers
41781184PMC13220113What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.